US Patent 7,959,946: Claim Scope, Expiration, Orange Book Status, and Generic Entry Risk

US Patent 7,959,946 protects a specific bilayer oral dosage form combining immediate-release pioglitazone hydrochloride with extended-release metformin hydrochloride. Its strongest protection is directed to the complete product architecture, not to pioglitazone, metformin, or their combination as pharmaceutical ingredients. A competing product must generally reproduce the claimed structural, dissolution, impurity, and release characteristics to present a direct infringement risk.

The patent’s baseline 20-year term runs from its earliest claimed priority date, November 22, 2004, producing a baseline expiration date of November 22, 2025, before any patent-term adjustment or extension. The patent is associated with Takeda’s Actoplus Met XR product family and should be analyzed with related continuation patents and FDA Orange Book listings.

What does US Patent 7,959,946 protect?

US Patent 7,959,946 protects a multilayer pharmaceutical dosage form containing:

A controlled-release metformin hydrochloride core.
A sustained-release coating surrounding the metformin core.
An optional rapidly dissolving seal coating.
An immediate-release pioglitazone hydrochloride layer surrounding the controlled-release core.
A surfactant-free pioglitazone layer.
Defined pioglitazone dissolution performance.
Defined impurity limits after accelerated storage.
In several dependent claims, an osmotic metformin tablet with specified composition and dissolution profiles.

The patent does not broadly claim every co-formulation of metformin and pioglitazone. The asserted product must fall within the particular dosage-form structure and performance limitations recited in the claims.

Core technical concept

The claimed dosage form places immediate-release pioglitazone on or around a controlled-release metformin tablet. The metformin component is designed to release over an extended period, while pioglitazone is released rapidly.

The claim architecture is consistent with a product intended to provide:

Early pioglitazone exposure.
Delayed and extended metformin exposure.
A single-tablet combination product.
Controlled impurity formation during storage.
Reduced reliance on gelling or expanding polymers in the metformin core.

Which claims are independent in US Patent 7,959,946?

Claims 1 and 12 are the two principal independent claims.

Claim	Claim type	Principal subject matter
1	Independent	Dosage form with controlled-release metformin core and immediate-release pioglitazone layer
2	Dependent	Pioglitazone release of at least 100% within 45 minutes
3	Dependent	Total pioglitazone impurities not above 0.5%
4	Dependent	Individual impurity limit not above 0.20%
5	Dependent	Individual impurity limit not above 0.10%
6	Dependent	Controlled-release core is an osmotic tablet
7	Dependent	Detailed osmotic-tablet composition and membrane limitations
8	Dependent	Core substantially free of gelling or expanding polymer
9	Dependent	Metformin Tmax of 8 to 12 hours
10	Dependent	Pioglitazone Tmax of 1 to 12 hours
11	Dependent	Pioglitazone Tmax of 1 to 4 hours
12	Independent	Osmotic metformin tablet with defined dissolution profile and pioglitazone layer
13	Dependent	At least 95% pioglitazone release within 30 minutes
14	Dependent	At least 100% pioglitazone release within 30 minutes
15	Dependent	Osmotic core substantially free of gelling or expanding polymer
16	Dependent	Narrower metformin dissolution profile
17	Dependent	Individual impurity limit not above 0.20%
18	Dependent	Individual impurity limit not above 0.10%

Claims 1 and 12 provide the broadest practical enforcement positions, but each still contains multiple limitations. Claims 6, 7, 15, and 16 are narrower and require an osmotic metformin platform.

How broad is claim 1?

Claim 1 requires all of the following:

A dosage form with two active drugs.
The metformin portion must contain only metformin hydrochloride as the active drug.
Metformin must be in a controlled-release core.
The core must have a sustained-release coating.
Pioglitazone hydrochloride must form an immediate-release layer around the coated core or optional seal coat.
The pioglitazone layer must contain a binder.
The pioglitazone layer must be free of a surfactant.
At least 90% of pioglitazone must release within 30 minutes under the specified USP 26 conditions.
After three months at 40°C and 75% relative humidity, total listed pioglitazone impurities must not exceed 0.6%.
No individual listed impurity may exceed 0.25%.

The claim therefore combines structural limitations with laboratory-performance limitations. A product could avoid literal infringement by using a different dosage-form arrangement, a surfactant-containing pioglitazone layer, a non-layered co-matrix, or release and impurity characteristics outside the claimed ranges.

The phrase “only one active drug that consists of metformin hydrochloride” limits the controlled-release core. A core containing another active pharmaceutical ingredient would create a potential noninfringement position under the literal language of the claim, although the total product would still need analysis under other claims or the doctrine of equivalents.

What formulations are protected by claims 6 and 7?

Claims 6 and 7 protect an osmotic metformin tablet. Claim 7 specifies the principal composition ranges:

Component	Claimed range
Metformin hydrochloride	50% to 98%
Binding agent	0.1% to 40%
Absorption enhancer	0% to 20%
Lubricant	0% to 5%
Polymer in sustained-release membrane	50% to 99%
Flux enhancer	0% to 40%
Plasticizer	0% to 25%

The membrane must include at least one passageway for metformin release. This is a classic osmotic delivery limitation: water enters through the membrane, dissolves or disperses the drug-containing core, and drives drug release through a formed passageway.

The claim does not require a particular polymer, flux enhancer, plasticizer, or passageway geometry. It instead uses percentage ranges and functional structure. A product may fall within claim 7 even if its exact excipient names differ, provided the composition and membrane meet the recited ranges.

What dissolution profiles are required?

Claim 1 requires rapid pioglitazone release. Claims 12 and 16 add specific metformin release profiles.

Pioglitazone release

The principal pioglitazone limitations are:

Claim	Required release
1	At least 90% within 30 minutes
2	At least 100% within 45 minutes
13	At least 95% within 30 minutes
14	At least 100% within 30 minutes

The test conditions are specified in the claims: USP 26 Apparatus 1, 100 rpm, 37°C, 900 mL of 0.3 M KCl-HCl buffer at pH 2.0.

Metformin release under claim 12

Claim 12 requires a USP Type 2 dissolution test in 900 mL of simulated intestinal fluid at pH 7.5, 75 rpm, and 37°C.

Time	Metformin release range or minimum
2 hours	0% to 25%
4 hours	10% to 45%
8 hours	30% to 90%
12 hours	At least 50%
16 hours	At least 60%
20 hours	At least 70%

Claim 16 narrows the profile:

Time	Metformin release range or minimum
2 hours	0% to 15%
4 hours	20% to 40%
8 hours	45% to 90%
12 hours	At least 60%
16 hours	At least 70%
20 hours	At least 80%

A generic applicant would normally need comparative dissolution data across multiple time points. A single passing or failing time point would not resolve infringement because the claims contain a series of cumulative release limitations.

What impurity limits are protected?

The patent identifies five pioglitazone-related compounds and imposes stability limits. Claim 1 requires:

Total listed pioglitazone impurities of no more than 0.6%.
Each individual impurity of no more than 0.25%.

Claims 3 through 5 narrow the total and individual limits:

Claim	Total impurity limit	Individual impurity limit
1	0.60%	0.25%
3	0.50%	0.25%
4	0.50%	0.20%
5	0.50%	0.10%

Claims 12, 17, and 18 use individual impurity limitations of 0.25%, 0.20%, and 0.10%, respectively.

These limitations are material because they are tested after storage under accelerated conditions. A product that meets the dissolution and structural requirements but exceeds the stated impurity thresholds may avoid literal infringement of the relevant claim.

The impurity limitations also create a product-development barrier. A manufacturer must control pioglitazone degradation while placing the active drug in a layer directly adjacent to a controlled-release metformin tablet and its coating materials.

When does US Patent 7,959,946 lose exclusivity?

The patent’s earliest priority date is November 22, 2004. Under the standard patent-term calculation, the baseline expiration date is November 22, 2025. The final effective date must account for any patent-term adjustment, patent-term extension, terminal disclaimer, or other recorded USPTO event.

Event	Date
Earliest claimed priority	November 22, 2004
Patent grant	August 2, 2011
Baseline 20-year expiration	November 22, 2025
Possible term adjustment or extension	Must be confirmed in USPTO and Orange Book records

The patent was granted after the Hatch-Waxman framework became applicable. FDA Orange Book listings, rather than the patent grant date alone, determine the patent information that an abbreviated new drug application applicant must address.

What is the Orange Book status of US Patent 7,959,946?

US Patent 7,959,946 is associated with the Actoplus Met XR combination product, which contains pioglitazone hydrochloride and extended-release metformin hydrochloride. Actoplus Met XR was approved through an FDA new drug application for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise.[2]

The Orange Book analysis should distinguish between:

Patents listed against immediate-release Actoplus Met.
Patents listed against extended-release Actoplus Met XR.
Patents covering the active ingredients individually.
Patents covering the combination product.
FDA regulatory exclusivity, which is separate from patent exclusivity.

A patent listing does not establish validity or enforceability. It identifies patents that the NDA holder represented as relevant to the approved product or an approved method of use.

Are there Paragraph IV challenges to this patent?

A Paragraph IV certification against US Patent 7,959,946 would state that the patent is invalid, unenforceable, or would not be infringed by the proposed generic product. The patent’s relevance to a generic application depends on whether the proposed product uses:

A bilayer or layered configuration.
Immediate-release pioglitazone surrounding a controlled-release metformin tablet.
An osmotic metformin system.
A surfactant-free pioglitazone layer.
The claimed dissolution profiles.
The specified impurity thresholds.

A generic applicant could pursue several design-around positions:

Use a matrix-based extended-release metformin tablet instead of an osmotic tablet.
Place pioglitazone and metformin in separate matrix regions rather than a surrounding layer.
Add a surfactant to the pioglitazone layer.
Use a different release mechanism for metformin.
Alter coating composition or passageway design.
Develop a product with different dissolution characteristics.
Use a capsule containing separate multiparticulates rather than a layered tablet.

A Paragraph IV filing would trigger a potential 30-month stay if the NDA holder or patent owner filed a timely infringement action under the Hatch-Waxman statute.[3] The patent text alone does not establish the existence, outcome, or terms of any particular Paragraph IV settlement.

What patent litigation affects Actoplus Met XR?

Patent litigation risk should be separated into three categories:

Product patent litigation

This concerns patents such as US 7,959,946 that claim the physical combination product. The central questions are whether the proposed generic has the claimed architecture and whether its testing data meet the claimed performance limitations.

Active-ingredient litigation

Pioglitazone and metformin each had substantial historical patent activity. Those patents do not necessarily cover a combined extended-release product, but they may affect the date on which a generic could market individual components or other dosage forms.

Regulatory exclusivity disputes

FDA exclusivity, patent listing disputes, and patent-term calculations can affect approval timing even when the product patent is vulnerable on the merits. These disputes are separate from a conventional infringement action.

No conclusion on infringement or validity should be drawn from the existence of the patent listing alone. Claim construction, product samples, ANDA formulation data, dissolution results, and impurity data would control.

How strong is the patent estate for Actoplus Met XR?

The patent estate is strongest against a generic that copies the original product design. Its practical strengths are:

Multiple limitations concentrated in the finished dosage form.
Specific osmotic-tablet claims.
Multiple dissolution checkpoints.
Accelerated-stability impurity requirements.
Dependent claims covering narrower release and impurity profiles.
Potential coverage of both structure and performance.

Its principal weaknesses are:

Narrow claim construction.
Dependence on test conditions and analytical methods.
Potential design-around options.
Limited protection against non-layered combination products.
Possible invalidity challenges based on written description, enablement, anticipation, obviousness, or indefiniteness.

The patent does not prevent a competitor from selling all metformin/pioglitazone combinations. It targets a defined delivery platform.

What manufacturing and intellectual-property barriers exist?

The formulation presents several manufacturing challenges:

Compression or manufacture of a high-load metformin core.
Application of a uniform sustained-release membrane.
Formation of a reliable osmotic passageway.
Application of an immediate-release pioglitazone layer.
Prevention of interaction between pioglitazone and coating excipients.
Control of impurity growth during accelerated storage.
Reproducible dissolution across commercial-scale batches.

The manufacturing process itself may be protected by separate process patents, trade secrets, or know-how even when the finished-product claims are avoided. A freedom-to-operate review should therefore include coating methods, laser drilling or passageway formation, excipient combinations, and stability-control systems.

How does the patent compare with a conventional metformin/pioglitazone tablet?

Issue	US 7,959,946 dosage form	Conventional combination tablet
Metformin release	Controlled or osmotic	Often immediate or matrix-controlled
Pioglitazone release	Immediate	May be immediate
Physical arrangement	Pioglitazone layer around coated metformin core	Single matrix or mixed tablet
Osmotic membrane	Required for narrower claims	Usually absent
Surfactant limitation	Pioglitazone layer must be surfactant-free	No corresponding requirement
Dissolution limitations	Detailed time-point requirements	Product-specific
Impurity limits	Expressly claimed	Not necessarily claimed
Design-around potential	Moderate to high	Usually outside literal scope

Key Takeaways

US Patent 7,959,946 claims a layered combination dosage form, not metformin or pioglitazone broadly.
Claims 1 and 12 are the principal independent claims.
The strongest claim scope covers immediate-release pioglitazone surrounding a controlled-release, often osmotic, metformin tablet.
Dissolution performance and pioglitazone impurity limits are substantive claim limitations.
Claims 6, 7, 15, and 16 create narrower protection for osmotic metformin systems.
The baseline patent expiration date is November 22, 2025, subject to recorded patent-term adjustments or extensions.
Generic risk is highest for products that replicate the layered osmotic-tablet architecture and release profiles.
Matrix tablets, capsules containing separate units, surfactant-containing pioglitazone layers, and other non-layered designs offer potential design-around paths.
FDA Orange Book listing status and any patent-term adjustment should be checked against the current USPTO and FDA records before a launch or litigation decision.

FAQs

Does US Patent 7,959,946 cover all Actoplus Met products?

No. Its claims are directed to a specific dosage form combining immediate-release pioglitazone with controlled-release metformin. Immediate-release or differently structured products require separate analysis.

Can a generic avoid the patent by using metformin extended-release matrix technology?

Potentially. A matrix formulation may avoid claims requiring an osmotic tablet, but claim 1 is not limited to an osmotic core. The complete formulation must be evaluated against the structural, dissolution, and impurity limitations of the asserted claim.

Does exceeding the pioglitazone impurity limit avoid infringement?

It may avoid literal infringement of a claim containing that impurity limitation, but the product could still fall within another claim or related patent. Analytical testing must follow the claim’s specified storage and HPLC conditions.

Is US 7,959,946 a patent on the pioglitazone-metformin combination itself?

No. The patent claims a particular pharmaceutical dosage form and release behavior. It does not broadly monopolize every pharmaceutical composition containing both active ingredients.

What is the principal commercial risk after patent expiry?

The principal risk is accelerated generic competition against the approved extended-release combination product. The timing depends on remaining patents, regulatory exclusivity, Paragraph IV litigation, settlement terms, manufacturing capacity, and the commercial attractiveness of the product.

References

United States Patent and Trademark Office. (2011). U.S. Patent No. 7,959,946, Pharmaceutical dosage form.
U.S. Food and Drug Administration. (n.d.). Actoplus Met XR: Prescribing information and approval records.
U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations: Orange Book.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).
United States Patent and Trademark Office. (2024). Patent term adjustment and patent term extension records.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-001	May 12, 2009		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-002	May 12, 2009		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	054238	⤷ Start Trial
Australia	2003272504	⤷ Start Trial
Australia	2004283059	⤷ Start Trial
Australia	2006232993	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,959,946

Which drugs does patent 7,959,946 protect, and when does it expire?

Summary for Patent: 7,959,946